The mutation rate of the Omicron sublineage has led to baseline resistance against all
previously authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more …

COVID-19 in immunocompromised hosts has emerged as a difficult therapeutic
management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 …

Background The role of host immunity in emergence of evasive SARS-CoV-2 Spike
mutations under therapeutic monoclonal antibody (mAb) pressure remains to be explored …

Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

The world is facing up the most considerable vaccination effort in history to end the
Coronavirus disease 2019 (COVID-19) pandemic. Several monoclonal antibodies (mAbs) …

Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat …

Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

COVID-19 patients at risk of severe disease may be treated with neutralising monoclonal
antibodies (mAbs). To minimise virus escape from neutralisation these are administered as …

We explored the molecular evolution of the spike gene after the administration of anti-spike
monoclonal antibodies in patients with mild or moderate forms of COVID-19. Four out of the …